Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Clinical lymphoma, myeloma & leukemia |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.clml.2012.11.012 |
| Field | Oncology and hematology |
| Keywords | Multiple myeloma; Thalidomide; Bortezomib; Chromosomal aberrations; FISH; Survival |
| Attached files | |
| Description | Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described. We analyzed the prognostic value of an extended panel of chromosomal aberrations [del(13)(q14), del(17)(p13), t(4;14)(p16;q32), gain(1)(q21), and hyperdiploidy] by using the technique of interphase fluorescence in situ hybridization in a cohort of 102 patients with relapsed MM treated with thalidomide- or bortezomib-based protocols. We conclude that bortezomib-based protocols are able to partially overcome the negative prognostic impact of the tested chromosomal abnormalities in patients with relapsed MM. |
| Related projects: |
|